Table 5.6d

Immunosuppression Use for Maintenance by Regimen

Prior to Discharge, 1995 to 2004

Recipients with Kidney Transplants

  Transplant Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Functioning Graft at Discharge 10,590 10,888 11,240 11,990 12,268 13,098 13,811 14,322 14,677 15,536
With Immunosuppression Info 10,363 10,685 11,194 11,924 12,083 12,875 13,775 14,258 14,601 15,225
--- + MMF/MPA 0.1% 0.0% 0.1% 0.3% 0.1% 0.1% 0.1% 0.2% 0.4% 0.4%
--- + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.2% 0.4% 0.6%
--- + MMF/MPA + Steroids 1.0% 2.0% 2.4% 2.6% 2.8% 1.6% 1.4% 1.2% 1.6% 1.7%
--- + OtherAntimet 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + OtherAntimet + Steroids 3.7% 3.6% 0.5% 0.3% 0.3% 0.1% 0.1% 0.1% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.3% 0.1% 0.2% 0.3%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.1% 0.2% 0.5% 0.5% 0.4% 0.6% 0.4%
--- + Steroids 1.8% 5.3% 1.5% 2.1% 1.9% 1.2% 1.0% 0.8% 1.3% 1.7%
CyA 0.3% 0.3% 0.4% 0.3% 0.2% 0.1% 0.1% 0.1% 0.2% 0.2%
CyA + MMF/MPA 0.1% 0.6% 0.5% 0.7% 0.6% 0.9% 0.9% 0.7% 1.6% 1.6%
CyA + MMF/MPA + OtherAntimet 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.2% 0.2% 0.0%
CyA + MMF/MPA + Steroids 10.5% 39.2% 50.0% 48.2% 46.7% 37.1% 27.7% 22.9% 18.3% 14.3%
CyA + OtherAntimet 0.3% 0.4% 0.3% 0.2% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Steroids 57.2% 23.1% 14.5% 8.8% 5.7% 3.6% 2.1% 0.8% 0.4% 0.2%
CyA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.4% 0.9% 1.2%
CyA + Siro/Evero + Steroids 0.1% 0.7% 1.5% 2.9% 1.9% 5.0% 3.6% 2.9% 2.2% 1.4%
CyA + Steroids 11.9% 8.6% 6.2% 5.4% 5.0% 3.1% 1.7% 1.2% 1.4% 1.4%
Tac 0.1% 0.1% 0.1% 0.1% 0.2% 0.6% 1.1% 2.0% 1.0% 1.2%
Tac + MMF/MPA 0.0% 0.1% 0.3% 0.6% 0.8% 1.1% 1.7% 2.9% 6.6% 13.8%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 0.4% 1.2% 0.7%
Tac + MMF/MPA + Steroids 1.0% 6.0% 12.5% 20.1% 26.3% 31.3% 38.5% 46.1% 46.8% 46.7%
Tac + OtherAntimet 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.1% 0.0% 0.1% 0.1%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet + Steroids 2.2% 2.1% 1.9% 1.9% 1.4% 1.1% 1.3% 1.1% 0.9% 0.5%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 1.2% 1.3% 1.7% 1.8%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.0% 0.2% 4.4% 6.4% 4.8% 4.7% 3.4%
Tac + Steroids 2.6% 3.3% 2.9% 2.9% 3.2% 3.5% 3.8% 3.3% 2.3% 2.4%
Other Regimen 7.2% 4.2% 4.1% 2.3% 2.3% 3.7% 5.5% 6.0% 4.9% 3.7%


Source: OPTN/SRTR Data as of May 2, 2005.

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.